RESEARCH TRIANGLE PARK, NORTH CAROLINA -- (MARKET WIRE) -- October 03, 2006 -- Adherex Technologies Inc. (TSX: AHX)(AMEX: ADH), a biopharmaceutical company with a broad portfolio of oncology products under development, today announced the initiation of a Phase I trial of ADH-1 in combination with chemotherapy in conjunction with the US Oncology Research network. The trial will be offered at 10 sites in the network's innovative Translational Oncology Phase 1 Research program chaired by Daniel D. Von Hoff, MD, US Oncology's Chief Scientific Officer.
